Poster 2924/9 presented at AACR 2022

Presenter: Yuehan Feng
Session: PO.CH02.01 – Structural and Chemical Biology
Date: April 12

John L Marshall, Beth N Peshkin, Takayuki Yoshino, Jakob Vowinckel, Håvard E Danielsen, Gerry Melino, Ioannis Tsamardinos, Christian Haudenschild, David J Kerr, Carlos Sampaio, Sun Young Rha, Kevin T FitzGerald, Eric C Holland, David Gallagher, Jesus Garcia-Foncillas, Hartmut Juhl. The Oncologist.

Within the last decade, the science of molecular testing has evolved from single gene and single protein analysis to broad molecular profiling as a standard of care, quickly transitioning from research to practice. Terms such as genomics, transcriptomics, proteomics, circulating omics, and artificial intelligence are now commonplace, and this rapid evolution has left us with a significant knowledge gap within the medical community. In this paper, we attempt to bridge that gap and prepare the physician in oncology for multiomics, a group of technologies that have gone from looming on the horizon to become a clinical reality. The era of multiomics is here, and we must prepare ourselves for this exciting new age of cancer medicine.

View Publication

Poster 3923/19 presented at AACR 2022

Presenter: Jakob Vowinckel
Session: PO.CH03.01 Proteomics, Signaling Networks, and Biomarker Discovery
Date: April 13

Preclinical drug development involves in-vivo discovery studies whereby essential model organisms, including mouse and rat help to understand human biology and disease. Despite genetic similarities, distinctions in gene expression between humans and relevant model organisms underscore the challenge of translatability.

E-Poster presented at SITC 2021

Presenter: Kristina Beeler
Poster Number: 90

Our latest white paper highlights our advanced plasma proteomics capabilities, driven by the P2 Enrichment System. The study demonstrates how TrueDiscovery^® Plasma Biomarker Discovery services achieve an optimal balance between depth, throughput, and sensitivity, enabling their application in informed clinical decision-making.

This poster, shown at the American Society of Hematology 2023 Annual Meeting with Roche and the University of Basel, delves into the impact of rhPTX2 immunotherapy on mouse Myeloproliferative neoplasms. It leverages insights from plasma proteome profiling generated with our TrueDiscovery^® platform.

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More